Arcellx and Aardvark Therapeutics Compared

Analyzing the strengths and differences between two medical companies

Mar. 17, 2026 at 7:50am

Got story updates? Submit your updates here. ›

Arcellx (NASDAQ:ACLX) and Aardvark Therapeutics (NASDAQ:AARD) are both medical companies, but which one is the better business? This article compares the two companies across several key metrics, including net margins, return on equity, revenue, earnings per share, and valuation.

Why it matters

Understanding the relative strengths and weaknesses of Arcellx and Aardvark Therapeutics can help investors make more informed decisions about which company may be the better investment opportunity in the medical technology sector.

The details

The analysis shows that Aardvark Therapeutics has lower revenue but higher earnings than Arcellx. Additionally, Arcellx is trading at a lower price-to-earnings ratio, indicating it may be the more affordable of the two stocks. However, Aardvark Therapeutics outperforms Arcellx on 9 out of 13 factors compared.

  • The data and analysis in this article are current as of March 17, 2026.

The players

Arcellx, Inc.

A medical company that develops various immunotherapies for patients with cancer and other incurable diseases in the United States.

Aardvark Therapeutics, Inc.

A biotechnology company that develops novel small molecule therapeutics for obesity and metabolic diseases, headquartered in San Diego, CA.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights the key differences between Arcellx and Aardvark Therapeutics, providing investors with valuable insights to consider when evaluating which medical technology company may be the better investment opportunity.